Ezetimibe news

All news on Ezetimibe (also known as Zetia, Ezetrol, and (3R,4S)-1-(4-Fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone): plants, production capacities, investments and involved companies.

7 June 2026

Amgen: Repatha (evolocumab) cuts first major CV events 29% in high‑risk diabetes subgroup

VESALIUS‑CV subgroup shows evolocumab lowers first major cardiovascular events and LDL‑C; real‑world GLP‑1 persistence is low, curbing potential benefits.
28 March 2026

Amgen: Repatha cuts first major cardiovascular events 31% in high‑risk patients without significant atherosclerosis

VESALIUS‑CV subgroup (3,655 high‑risk diabetics without known atherosclerosis) showed a 31% reduction in first major CV events vs placebo; median LDL‑C 44 mg/dL over ~4.8 years.

Who will be producing Ezetimibe in the future?

Find out with chemXplore Alpha

Learn more